paliperidone
Also known as 9-hydroxyrisperidone, Invega®, Ro-76477, Ro-92670, Trevicta, 9-Hydroxyrisperidone
Paliperidone, sold under the brand name Invega among others, is an atypical antipsychotic. It is used for the treatment of schizophrenia and schizoaffective disorder. It is marketed by Janssen Pharmaceuticals.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 461753832
- Drug.image
- Paliperidone.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.tradename
- Invega, others
- Drug.MedlinePlus
- a607005
- Drug.DailyMedID
- Paliperidone
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth, intramuscular
- Drug.class
- Atypical antipsychotic
- Drug.ATC_prefix
~7 min read
Article
11 sectionsContents
- Medical use
- Adverse effects
- Pharmacology
- History
- Society and culture
- Deaths
- Suicides
- Homicides
- Brand names
- References
- External links
Paliperidone, sold under the brand name Invega among others, is an atypical antipsychotic. It is used for the treatment of schizophrenia and schizoaffective disorder. It is marketed by Janssen Pharmaceuticals.
Paliperidone was approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia in December 2006, and in the European Union in June 2007. Paliperidone palmitate is a long-acting injectable formulation of paliperidone palmitoyl ester. It is on the World Health Organization's List of Essential Medicines. Paliperidone is available as a generic medication.
Connections
Categories
Alpha-2 blockersAntiaggressive drugsAntipsychotic estersAtypical antipsychoticsBelgian inventionsChemical articles with multiple CAS registry numbersChemical articles with multiple ChEBIsChemical articles with multiple PubChem CIDsChemicals using indexlabelsCitation overkillDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fields